German Joy For Pharma As Drug Discount Prices Stay Hidden
This article was originally published in The Pink Sheet Daily
Executive Summary
The updated German Pharmaceutical Act will ensure that drug prices negotiated there between pharmaceutical manufacturers and health insurers will remain hidden from public view, as Germany’s government seeks to avoid a pan-European drug price crash.
You may also be interested in...
With New Mechanism, Can Eisai’s Fycompa Make Its Mark In Epilepsy?
Efficacy results were not uniformly positive in pivotal trials of newly approved perampanel, but FDA explains that may be due to high placebo rates in some international sites.
Eisai Wins FDA Approval For Novel, Once-Daily Seizure Drug Fycompa
Eisai’s Fycompa becomes only the second drug with a new mechanism of action approved by FDA for epilepsy in the last decade.
Reversal Of Fortune For German Pharma As Bundesrat Supports Enhanced Drug Price Transparency
Germany’s upper house of parliament, the Bundesrat, has decided after considerable wrangling that negotiated and discounted reimbursement prices of drugs sold in Europe’s biggest market will be made public, virtually ensuring that further price erosion will spread across the region.